Hypertension, also known as high blood pressure, is a common and dangerous condition. It affects over 1 billion people worldwide.
Having high blood pressure means the pressure of the blood in your blood vessels is higher than it should be.
High blood pressure is called the “silent killer” because it often has no warning signs or symptoms, and many people do not know they have it. Therefore, it is important to check your blood pressure regularly.
Left uncontrolled, hypertension significantly increases the risk of stroke and heart disease.
According to the World Health Organization (WHO), high blood pressure is a major risk factor for coronary heart disease and ischemic as well as hemorrhagic stroke.
- In some age groups, the risk of cardiovascular disease doubles for each increment of 20/10 mmHg of blood pressure, starting as low as 115/75 mmHg.
- In addition to coronary heart diseases and stroke, complications of raised blood pressure include heart failure, peripheral vascular disease, renal impairment, retinal hemorrhage and visual impairment.
- Treating systolic blood pressure and diastolic blood pressure until they are less than 140/90 mmHg is associated with a reduction in cardiovascular complications.
Pioneering Device-Based Treatment
Appropriate lifestyle changes are the cornerstone for the prevention of hypertension and are also important for its treatment. If your resting blood pressure falls in the pre-hypertension range (systolic between 120 and 139 mmHg OR diastolic between 80 and 89 mmHg), your doctor will recommend lifestyle modifications.1,2
If your blood pressure remains 140/90 mmHg or higher despite appropriate lifestyle changes or in the case of persistently elevated out-of-office blood pressure, your physician will likely prescribe antihypertensive medications.2
A New Area Of Research
For patients unable to effectively control their blood pressure with lifestyle changes and medication therapy, a new class of interventional catheters are under development for the treatment of hypertension.
Ablative Solutions is on the forefront of this new field of research with its Peregrine System Kit.
The Peregrine System Infusion Catheter
The Peregrine System Infusion Catheter for Transcatheter Perivascular Denervation
The sympathetic nerve system plays an important role in maintaining your body’s balance – sending messages between your brain and organs. If, however, the nerves are overactive and send too many signals, that can contribute to high blood pressure. Physicians have demonstrated that interrupting nerve paths contributing to overactive signaling can help reduce blood pressure.
Ablative Solutions is on the forefront of this new field of research called renal denervation. The Peregrine System developed by Ablative Solutions offers the potential to provide enhanced delivery of renal denervation therapy for the treatment of systemic hypertension. This novel approach being developed by Ablative Solutions is called Transcatheter Perivascular Denervation.
The Peregrine catheter is a flexible infusion catheter that is placed by an interventionalist using a catheter-based approach. Using a technique very similar to routine coronary or peripheral catheterization, the device is advanced through the femoral artery, and then into the renal artery. Once positioned in the renal artery, the Peregrine catheter is used to infuse a neurolytic agent into the space surrounding the renal artery where the sympathetic nerves are located, called the ‘perivascular’ space. This creates a denervated zone that blocks the signals contributing to hypertension.
The procedure is done under mild-sedation, with the potential for a shorter hospital stay.
Ablative Solutions is committed to advancing the treatment of systemic hypertension through robust clinical research.
In May 2015, the device received CE mark approval in Europe for the treatment of hypertension. Prior to commercialization, the Company is conducting further European clinical studies in select centers to gather additional clinical data.
If you have high blood pressure, you may be eligible to participate. For more information about eligibility and enrolling sites, please contact: Clinical-EU@ablativesolutions.com
1American Heart Association
2 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension